Table 2

Indication for liver biopsy and final diagnoses
Indication N (%)
Potentially malignant lesion 1125 (50.5%)
Hepatitis 576 (25.8%)
Transaminase elevation 76 (3.4%)
Abscess/cyst 66 (3.0%)
Hepatopathy, hepatomegaly 161 (7.2)
Lymphoma 30 (1.4)
Metabolic disorders (Wilson’s disease, hemochromatosis, hemosiderosis) 30 (1.4)
Cirrhosis 22 (1.0)
Autoimmune disorder (autoimmune hepatitis, PBC, PSC) 87 (3.9)
Rejection reaction after liver transplantation 4 (0.2)
Jaundice of unclear origin 1 (0.04)
Thalassemia 4 (0.2)
Echinococcus infestation 3 (0.1)
NASH, ASH, steatosis 13 (0.6)
Cholestasis 10 (0.5)
Sarcoidosis 11 (0.5)
Bilioma 2 (0.1)
Hemangioma 1 (0.04)
Ascites 3 (0.1)
Still’s disease 1 (0.04)
Alpha-1 antitrypsin deficiency 2 (0.1)
Vasculitis 1 (0.04)
Final diagnoses N (%)
Diffuse liver diseases
Viral hepatitis 336 (15.1%)
Autoimmune disorders 43 (1.9%)
Hepathopathy (NASH, ASH, steatosis, chronic hepatitis, drug-induced liver damage, nutritional-toxic damage, fibrosis, cirrhosis, liver necrosis, hepatosis, cholangitis, cholestasis, Budd-Chiari Syndrome) 624 (28.0%)
Metabolic disorders 12 (0.5%)
Rejection reaction following liver transplantation 5 (0.2%)
Sarcoidosis 3 (0.1%)
Carcinomas of hepatic origin (HCC, CCC) 112 (5.0%)
Benign liver tumors
Hemangioma 14 (0.6%)
Cysts 13 (0.6%)
Focal nodular hyperplasia 13 (0.6%)
Metastases 590 (26.5%)
Poorly differentiated carcinomas 30 (1.4%)
Echinococcosis 4 (0.2%)
Abscess 42 (1.9%)
Ascites 1 (0.04%)
Adenoma 2 (0.1%)
Bilioma 2 (0.1%)
Mucor mycosis 1 (0.04%)
Ethanol instillation (intervention) 12 (0.5%)
No pathological findings 307 (7.3%)
Non-diagnostic puncture 63 (2.8%)

ASH alcoholic steatohepatitis, CCC Cholangiocarcinoma, HCC Hepatocellular carcinoma, NASH nonalcoholic steatohepatitis, PBC Primary biliary cirrhosis, PSC Primary sclerosing cholangitis.

Mueller et al.

Mueller et al. BMC Gastroenterology 2012 12:173   doi:10.1186/1471-230X-12-173

Open Data